Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APVOOTCMKTS:ARGSQOTCMKTS:GPLBOTCMKTS:VGLS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPVOAptevo Therapeutics$3.01-1.0%$6.06$2.81▼$485.37$2.28M5.58605,150 shs126,246 shsARGSQArgos Therapeutics$0.05$0.05$0.02▼$0.25$572K2.4713,394 shsN/AGPLBGreen Planet Bioengineering$0.04$0.10$0.02▼$0.70$800K3.073,055 shsN/AVGLSVG Life Sciences$0.00$0.00$0.00▼$0.00$2.11M1.678.22 million shs2.30 million shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPVOAptevo Therapeutics+3.05%-6.17%-36.27%-92.36%-99.96%ARGSQArgos Therapeutics0.00%0.00%0.00%0.00%0.00%GPLBGreen Planet Bioengineering0.00%0.00%-63.64%-92.16%+7,900.00%VGLSVG Life Sciences0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPVOAptevo Therapeutics2.1121 of 5 stars3.53.00.00.00.60.01.3ARGSQArgos TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AGPLBGreen Planet BioengineeringN/AN/AN/AN/AN/AN/AN/AN/AVGLSVG Life SciencesN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPVOAptevo Therapeutics 3.00Buy$219,040.007,276,976.41% UpsideARGSQArgos Therapeutics 0.00N/AN/AN/AGPLBGreen Planet Bioengineering 0.00N/AN/AN/AVGLSVG Life Sciences 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPVOAptevo TherapeuticsN/AN/AN/AN/A$65.21 per shareN/AARGSQArgos Therapeutics$1.90M0.30N/AN/A($1.63) per share-0.03GPLBGreen Planet BioengineeringN/AN/AN/AN/AN/AN/AVGLSVG Life SciencesN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPVOAptevo Therapeutics-$24.13MN/A0.00N/AN/AN/A-779.42%-175.59%8/6/2025 (Estimated)ARGSQArgos Therapeutics-$40.57MN/A0.00∞N/AN/AN/AN/AN/AGPLBGreen Planet BioengineeringN/AN/A0.00∞N/AN/AN/AN/AN/AVGLSVG Life SciencesN/AN/A0.00∞N/AN/AN/AN/AN/ALatest ARGSQ, APVO, GPLB, and VGLS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025APVOAptevo Therapeutics-$84.20-$87.80-$3.60-$4.39N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPVOAptevo TherapeuticsN/AN/AN/AN/AN/AARGSQArgos TherapeuticsN/AN/AN/AN/AN/AGPLBGreen Planet BioengineeringN/AN/AN/AN/AN/AVGLSVG Life SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPVOAptevo TherapeuticsN/A0.670.67ARGSQArgos TherapeuticsN/AN/AN/AGPLBGreen Planet BioengineeringN/AN/AN/AVGLSVG Life SciencesN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPVOAptevo Therapeutics8.06%ARGSQArgos TherapeuticsN/AGPLBGreen Planet BioengineeringN/AVGLSVG Life SciencesN/AInsider OwnershipCompanyInsider OwnershipAPVOAptevo Therapeutics0.01%ARGSQArgos Therapeutics28.21%GPLBGreen Planet BioengineeringN/AVGLSVG Life SciencesN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPVOAptevo Therapeutics50756,000756,000Not OptionableARGSQArgos Therapeutics12210.59 millionN/ANot OptionableGPLBGreen Planet Bioengineering120.01 millionN/ANot OptionableVGLSVG Life Sciences121.10 billionN/ANot OptionableARGSQ, APVO, GPLB, and VGLS HeadlinesRecent News About These CompaniesVGLS VG Life Sciences Inc. - Seeking AlphaJune 28, 2025 | seekingalpha.comCamfil USA Unveils Absolute® VG: Advanced V-Bank HEPA Filters with Gasket and Gel SealsOctober 31, 2024 | markets.businessinsider.comVG Life Sciences Inc.September 14, 2024 | barrons.comVG Life Sciences, Inc. Increases Authorized SharesAugust 16, 2024 | br.advfn.comVG Life Sciences Inc. Moves to Restore Financial Accountability & Completes Prior Year Audits, Plans to File Form 10August 16, 2024 | br.advfn.comVG Life Sciences Inc. (VGLS)March 1, 2024 | finance.yahoo.comVG Life Sciences Stock (OTC:VGLS), Insider Trading ActivityFebruary 27, 2024 | benzinga.comEmerging from a Recent Pullback, Life Sciences Has a PulseJanuary 18, 2024 | globest.comGVG Life Sciences Inc VGLSNovember 16, 2023 | morningstar.comMReport warns of 'oversupply' of life sciences real estateSeptember 17, 2023 | bizjournals.comVGLS VG Life Sciences Inc.February 16, 2023 | seekingalpha.comThe best Life is Strange game is on PlayStation Plus right now – and it’s not what you thinkJanuary 26, 2023 | vg247.comVNew MarketBeat Followers Over TimeMedia Sentiment Over TimeARGSQ, APVO, GPLB, and VGLS Company DescriptionsAptevo Therapeutics NASDAQ:APVO$3.01 -0.03 (-0.99%) As of 03:11 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. The company's lead clinical blood cancer candidate is APVO436 that is in Phase 1b/2 clinical trial for acute myelogenous leukemia. It is also developing ALG.APV-527, a novel investigational bispecific ADAPTIR candidate that is in Phase 1 clinical trial for NSCLC, head and neck, colorectal, pancreatic, breast, and other solid tumors; APVO603, a preclinical dual agonist bispecific ADAPTIR candidate for multiple solid tumors; APVO442, a novel bispecific candidate based on the ADAPTIR-FLEX platform technology for multiple solid tumors; and APVO711, a preclinical dual mechanism bispecific ADAPTIR candidate for prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.Argos Therapeutics OTCMKTS:ARGSQ$0.05 0.00 (0.00%) As of 10/10/2019Argos Therapeutics, Inc., an immuno-oncology company, focuses on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases in North America. The company develops immunotherapies based on its proprietary technology platform, Arcelis. Its product candidates include rocapuldencel-T, which is in Phase III clinical trial for the treatment of metastatic renal cell carcinoma. The company also develops AGS-004, which is in Phase II clinical trials for the treatment of human immunodeficiency virus. The company was formerly known as Merix Bioscience, Inc. and changed its name to Argos Therapeutics, Inc. in October 2004. Argos Therapeutics, Inc. was founded in 1997 and is based in Durham, North Carolina. On November 30, 2018, Argos Therapeutics, Inc. filed a voluntary petition for reorganization under Chapter 11 in the US Bankruptcy Court for the District of Delaware.Green Planet Bioengineering OTCMKTS:GPLB$0.04 0.00 (0.00%) As of 07/1/2025Green Planet Bioengineering Co. Ltd. operates as a shell company, with the purpose of acquisition and merging with an existing business operation. The company was founded on October 30, 2006 and is headquartered in Aventura, FL.VG Life Sciences OTCMKTS:VGLS$0.0001 0.00 (0.00%) As of 12:52 PM EasternVG Life Sciences Inc., a biotechnology company, researches and develops a pipeline of transformative therapies for combat cancer, infectious diseases, and autoimmune diseases caused by chronic inflammation. It offers VG1177, a solution that deploys a synthesized peptide, which uses its superior binding abilities to eliminate the unwanted Class II-associated invariant chain peptide (CLIP) that is displayed on specific B cells that leads to chronic inflammation. The company also provides metabolic disruption technology (MDT) compounds impede tumor cells that sensitize cancer cells to treatment by disrupting the metabolic strategies those cells use to survive; and Hydroxychloroquine, a MDT compound that can be used in combination with other cancer drugs for treating drug-resistant cancers. In addition, it offers targeted peptide technology (TPT), a technology that eliminates the subpopulation of pro-inflammatory immune cells and presents a possible treatment for autoimmune and infectious diseases. VG Life Sciences Inc. was formerly known as Viral Genetics Inc. and changed its name to VG Life Sciences Inc. in November 2012. The company was founded in 1995 and is based in Santa Barbara, California. VG Life Sciences Inc. operates as a subsidiary of Feelux Co., Ltd. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Rocket Lab: Latest Catalysts Bolster the Bull Case Nike's Stock Just Got an Upgrade: Is a Real Comeback Brewing? Why Hims & Hers Is a Buy Below $35 After Its 16% Pullback Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
